Paclitaxel trevatide

Drug Profile

Paclitaxel trevatide

Alternative Names: ANG-1005; GRN-1005; Paclitaxel peptide vector conjugate - Angiochem; Paclitaxel-AngioPep1-conjugate-Angiochem

Latest Information Update: 10 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AngioChem
  • Class Antineoplastics; Drug conjugates; Paclitaxels; Peptides
  • Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Brain metastases; Glioblastoma; Glioma

Most Recent Events

  • 01 Sep 2017 Angiochem completes a phase II trial in Glioblastoma and Glioma (Recurrent) in USA (IV) (NCT01967810)
  • 01 Sep 2017 Angiochem completes a phase II trial for Brain metastases from breast cancer in USA (IV) (NCT02048059)
  • 08 Dec 2016 Paclitaxel trevatide is still in phase II trials for Glioblastoma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top